文献速递性腺与生殖内分泌肥胖与代谢综合征

二甲双胍暴露对多囊卵巢综合征母亲子代胎儿生长与出生人体测量学的影响

Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

该研究为随机对照试验的事后分析,纳入258例多囊卵巢综合征(PCOS)母亲所生子代,比较妊娠早期至分娩服用二甲双胍2000 mg(n=131)与安慰剂(n=121)对胎儿生长和出生人体测量学的影响。结果显示,二甲双胍组子代在孕32周和出生时头径更大,且该效应仅见于超重/肥胖母亲;正常体重母亲中,二甲双胍组子代身长和体重z评分较低。与参考人群相比,PCOS母亲安慰剂组子代身长z评分降低,但出生体重和头围相似。

要点

  • 二甲双胍组子代在孕32周双顶径和出生时头围均大于安慰剂组。
  • 头径增大效应仅见于超重/肥胖母亲,正常体重母亲中二甲双胍组子代身长和体重z评分较低。
  • PCOS母亲安慰剂组子代身长z评分低于参考人群,出生体重和头围与参考人群相似。

核心结论

  • 二甲双胍暴露导致超重母亲子代头径增大,该效应在宫内即可追踪。
  • 母亲孕前BMI改变了二甲双胍对子代人体测量学的影响。
  • PCOS母亲子代的人体测量学与参考人群存在差异。

研究设计与样本

  • 研究设计为随机对照试验的事后分析,采用双盲、安慰剂对照、多中心设计。
  • 研究对象为258例PCOS母亲所生子代,二甲双胍组n=131,安慰剂组n=121。
  • 干预为从妊娠早期至分娩服用二甲双胍2000 mg或安慰剂。

主要发现

  • 二甲双胍组与安慰剂组子代在孕32周双顶径分别为86.1 mm vs 85.2 mm(P=0.03),出生时头围分别为35.6 cm vs 35.1 cm(P<0.01)。
  • 按母亲孕前BMI分层,头径增大仅见于超重/肥胖母亲子代。
  • 正常体重母亲中,二甲双胍组与安慰剂组子代身长z评分分别为-0.96 vs -0.42(P=0.04),体重z评分分别为-0.44 vs 0.02(P=0.03)。
  • 与参考人群相比,PCOS母亲安慰剂组子代身长z评分为-0.40(95%CI -0.60至-0.40),出生体重和头围相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metformin is used in an attempt to reduce pregnancy complications associated with polycystic ovary syndrome (PCOS). Little is known about the effect of metformin on fetal development and growth. OBJECTIVES: To compare the effect of metformin versus placebo on fetal growth and birth anthropometrics in PCOS offspring compared with a reference population in relation to maternal body mass index (BMI). DESIGN: Post hoc analysis of a randomized controlled trial. SETTING: Double-blind, placebo-controlled, multicenter study. PATIENTS: 258 offspring born to mothers with PCOS. INTERVENTION: 2000 mg metformin (n = 131) or placebo (n = 121) from first trimester to delivery. MAIN OUTCOME MEASURES: Mean abdominal diameter and biparietal diameter (BPD) at gestational weeks 19 and 32. Head circumference (HC), birth length, and weight related to a reference population of healthy offspring, expressed as gestational age- and sex-adjusted z-scores. RESULTS: Metformin- versus placebo-exposed offspring had larger heads at gestational week 32 (BPD, 86.1 mm versus 85.2 mm; P = 0.03) and at birth (HC, 35.6 cm versus 35.1 cm; P < 0.01). Analyses stratified by maternal prepregnancy BMI, larger heads were observed only among offspring of overweight/obese mothers. Among normal-weight mothers, the effect of metformin compared with placebo was reduced length (z-score = -0.96 versus -0.42, P = 0.04) and weight (z-score = -0.44 versus 0.02; P = 0.03). Compared with the reference population, offspring born to PCOS mothers (placebo group) had reduced length (z-score = -0.40; 95% confidence interval, -0.60 to -0.40), but similar birth weight and HC. CONCLUSIONS: Metformin exposure resulted in larger head size in offspring of overweight mothers, traceable already in utero. Maternal prepregnancy BMI modified the effect of metformin on offspring anthropometrics. Anthropometrics of offspring born to PCOS mothers differed from those of the reference population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hjorth-Hansen A, Salvesen Ø, Engen Hanem LG, et al. Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS. J Clin Endocrinol Metab. 2018. PMID: 29165598. doi:10.1210/jc.2017-01191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。